Zydus Lifesciences Partners with Guardant Health to Promote Advanced Cancer Testing in India & Nepal

The collaboration involved promoting the Guardant360 collection of tests, such as Guardant360 and Guardant360 TissueNext, offering comprehensive genomic profiling and the Guardant360 Response test for monitoring treatment responses.

Zydus Lifesciences Limited, a global life sciences company, has partnered with  Guardant Health, a US-based precision oncology leader, to promote advanced biopsy tests in India and Nepal jointly. 

The collaboration addresses the pressing need for enhanced cancer treatment options by leveraging state-of-the-art genomic tests.

The collaboration involved promoting the Guardant360 collection of tests, such as Guardant360 and Guardant360 TissueNext, offering comprehensive genomic profiling and the Guardant360 Response test for monitoring treatment responses. 

Also, the objective of this partnership was to equip oncologists with essential genomic tests that aid in administering the most appropriate targeted treatments for patients with advanced cancers. 

Simranjit Singh, chief executive officer of Guardant Health Asia, Middle East, and Africa, highlighted the significance of addressing unmet cancer treatment needs through these tests. He said, "This collaboration signifies our mutual commitment to improving cancer treatment outcomes by providing oncologists with valuable genomic tests."

Commenting on the same, a spokesperson from Zydus Lifesciences said, "Access to these critical diagnostic tests and precision oncology will significantly contribute to better clinical outcomes in the fight against advanced solid cancer."

The suite of biopsy tests offered a comprehensive view of the tumor's genetic makeup, aiding doctors in identifying the most suitable treatment based on the patient's tumor genomic profile. 

These tests not only facilitated the commencement of appropriate treatment but also allowed for the monitoring of treatment responses over time.

Zydus Lifesciences Limited, previously known as Cadila Healthcare Limited, is a leading global healthcare provider in the Indian pharmaceutical landscape. 

Established in 1952 by Ramanbhai B Patel, the company has evolved under the Zydus group, displaying substantial financial growth from a modest INR 250 Cr in 1995 to over INR 17,000 Cr in FY-21.

In parallel developments, Zydus Lifesciences, headquartered in Ahmedabad, acquired the UK-based LiqMeds Group of companies. This strategic move aimed to strengthen its position in the pharmaceutical domain further.

In a prior agreement, Zydus had authorised Sun Pharma to co-market a novel drug related to chronic kidney disease in India. This drug has been marketed by Zydus under the brand name Oxemia since 2022.